These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 25402275)

  • 1. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
    Oelze M; Kröller-Schön S; Welschof P; Jansen T; Hausding M; Mikhed Y; Stamm P; Mader M; Zinßius E; Agdauletova S; Gottschlich A; Steven S; Schulz E; Bottari SP; Mayoux E; Münzel T; Daiber A
    PLoS One; 2014; 9(11):e112394. PubMed ID: 25402275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
    Ojima A; Matsui T; Nishino Y; Nakamura N; Yamagishi S
    Horm Metab Res; 2015 Aug; 47(9):686-92. PubMed ID: 25611208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.
    Steven S; Oelze M; Hanf A; Kröller-Schön S; Kashani F; Roohani S; Welschof P; Kopp M; Gödtel-Armbrust U; Xia N; Li H; Schulz E; Lackner KJ; Wojnowski L; Bottari SP; Wenzel P; Mayoux E; Münzel T; Daiber A
    Redox Biol; 2017 Oct; 13():370-385. PubMed ID: 28667906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.
    Cheng ST; Chen L; Li SY; Mayoux E; Leung PS
    PLoS One; 2016; 11(1):e0147391. PubMed ID: 26807719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Treatment with Empagliflozin and GABA Improves
    Daems C; Welsch S; Boughaleb H; Vanderroost J; Robert A; Sokal E; Lysy PA
    J Diabetes Res; 2019; 2019():2813489. PubMed ID: 31467926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats.
    Shao Q; Meng L; Lee S; Tse G; Gong M; Zhang Z; Zhao J; Zhao Y; Li G; Liu T
    Cardiovasc Diabetol; 2019 Nov; 18(1):165. PubMed ID: 31779619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    J Pharm Pharmacol; 2014 Jul; 66(7):975-87. PubMed ID: 24533859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
    Lin B; Koibuchi N; Hasegawa Y; Sueta D; Toyama K; Uekawa K; Ma M; Nakagawa T; Kusaka H; Kim-Mitsuyama S
    Cardiovasc Diabetol; 2014 Oct; 13():148. PubMed ID: 25344694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress.
    Bugga P; Mohammed SA; Alam MJ; Katare P; Meghwani H; Maulik SK; Arava S; Banerjee SK
    Life Sci; 2022 Oct; 307():120862. PubMed ID: 35934058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus.
    Luippold G; Klein T; Mark M; Grempler R
    Diabetes Obes Metab; 2012 Jul; 14(7):601-7. PubMed ID: 22268612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
    Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
    Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
    Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
    Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
    Domon A; Katayama K; Sato T; Tochigi Y; Tazaki H; Suzuki H
    PLoS One; 2021; 16(5):e0251135. PubMed ID: 33945582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice.
    Ganbaatar B; Fukuda D; Shinohara M; Yagi S; Kusunose K; Yamada H; Soeki T; Hirata KI; Sata M
    Eur J Pharmacol; 2020 May; 875():173040. PubMed ID: 32114052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes.
    Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
    Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):211-223. PubMed ID: 27817207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats.
    Takeshige Y; Fujisawa Y; Rahman A; Kittikulsuth W; Nakano D; Mori H; Masaki T; Ohmori K; Kohno M; Ogata H; Nishiyama A
    Hypertens Res; 2016 Jun; 39(6):415-22. PubMed ID: 26818652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
    Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence.
    Khemais-Benkhiat S; Belcastro E; Idris-Khodja N; Park SH; Amoura L; Abbas M; Auger C; Kessler L; Mayoux E; Toti F; Schini-Kerth VB
    J Cell Mol Med; 2020 Feb; 24(3):2109-2122. PubMed ID: 30929316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats.
    Vallejo S; Palacios E; Romacho T; Villalobos L; Peiró C; Sánchez-Ferrer CF
    Cardiovasc Diabetol; 2014 Dec; 13():158. PubMed ID: 25518980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.